Essential Thrombocythemia
📧 Sign up to get email alerts when something new happens for Essential Thrombocythemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms [Phase 1, Phase 2]
The Phase 1/2 study evaluating the combination of ruxolitinib and CPX-351 in advanced phase myeloproliferative neoplasms was terminated, wit…
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms [Phase 1]
An update on a Phase 1 safety and tolerability study of INCB057643 in myelofibrosis and other advanced myeloid neoplasms, with the trial cur…
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm [Phase 2]
This Phase 2 trial update reports completion of a study evaluating the combination of ruxolitinib phosphate and azacitidine in patients with…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms [Phase 2]
Phase 2 clinical trial evaluating curcumin to improve inflammation and symptoms in patients with clonal cytopenia of undetermined significan…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating CPI-0610 with and without ruxolitinib in patients with hematologic and myeloproliferative malignancies. …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) [Phase 2]
Extension-phase update for bomedemstat (IMG-7289/MK-3543) in myeloproliferative neoplasms. The Phase 2 extension study in essential thromboc…
-
CLINICAL_TRIALS trial_result · 2025-06-10Clinical Trial Update: The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia [Phase 2]
Phase 2 clinical trial (Ruxo-BEAT) evaluating ruxolitinib in high-risk polycythemia vera or high-risk essential thrombocythemia; the study i…
-
CLINICAL_TRIALS trial_result · 2025-05-20Clinical Trial Update: Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 [Phase 2]
Phase 2 clinical trial update of IMG-7289, an LSD1 inhibitor, in essential thrombocythemia. The study is active but not recruiting, with res…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [Phase 1]
Phase 1 study of Veliparib with Topotecan, with or without Carboplatin, in relapsed or refractory acute leukemias, high-risk myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 clinical trial update from Bristol-Myers Squibb evaluating SAR302503 in polycythemia vera or essential thrombocythemia; the study st…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. [NA]
A completed pilot clinical trial evaluating a diagnostic score to differentiate myeloproliferative neoplasms, including essential thrombocyt…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) [Phase 2]
Phase 2 LIMBER-213 evaluated the safety, tolerability, and efficacy of Itacitinib immediate-release tablets in adults with primary or second…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]
Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including …
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders …
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) [Phase 2]
Phase 2 study of bomedemstat in essential thrombocythemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Myeloproliferative Neoplasms: an In-depth Case-control Study
A completed clinical trial examining myeloproliferative neoplasms with results posted; focuses on Polycythemia Vera, Essential Thrombocythem…
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Dual Vaccine Trial in Myeloproliferative Neoplasms [Phase 1, Phase 2]
A dual vaccine trial in myeloproliferative neoplasms completed Phase 1/2 testing for polycythemia vera and essential thrombocythemia.
-
CLINICAL_TRIALS trial_result · 2023-02-27Clinical Trial Update: Agrylin Drug Use-Result Survey
Clinical trial update for Agrylin (anagrelide) showing results from a completed study on essential thrombocythemia; results posted.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-04-27Clinical Trial Update: A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms [Phase 3]
A Phase 3 trial comparing low-dose interferon alpha with hydroxyurea in chronic myeloid neoplasms has completed.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) [Phase 2]
Phase 2 study comparing ruxolitinib to anagrelide in essential thrombocythemia patients resistant to or intolerant of hydroxyurea; the trial…
-
CLINICAL_TRIALS trial_result · 2021-11-04Clinical Trial Update: Arterial Function and Atherosclerosis in Essential Thrombocythemia
A completed clinical trial assessing arterial function and atherosclerosis in patients with essential thrombocythemia.
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: Anagre Cap. in Patients With High-Risk Essential Thrombocythemia [Phase 4]
Phase 4 clinical trial update for Anagre Cap. in high-risk essential thrombocythemia has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-29Clinical Trial Update: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line [Phase 2, Phase 3]
A phase 2/3 trial evaluating ruxolitinib versus best available therapy in high-risk essential thrombocythemia in second-line treatment was t…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia [Phase 2]
Phase 2 long-term safety and efficacy update for momelotinib in various myelofibrosis subtypes; study completed with results posted in 2021.